Idorsia announces financial results for 2022 – building momentum
to become a leading mid-sized biopharmaceutical company
More momentum
Simon Jose, our CCO
takes us through
"The year of launch"
Mathieu Simon, Chairman
“The rapid progress made by Idorsia in a relatively short time is a huge achievement.”
Jean-Paul Clozel, CEO
“2022 was a transformative year for Idorsia – and our achievements have laid the foundations for success in 2023.”
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
News
| 17 Mar 2023 | |
| 07 Feb 2023 | |
| 06 Feb 2023 | |
| 31 Jan 2023 | |
| 09 Jan 2023 |
Events
| Event | When |
|
Credit Suisse London Healthcare Conference
|
February 28 - March 1, 2023 |
|
Barclay's Healthcare Conference
|
March 14-15, 2023 |
|
Jefferies 3rd Pan European Mid Cap Conference
|
March 28-30, 2023 |
|
First Quarter 2023 Financial Results reporting*
|
April 25, 2023 |
|
Annual General Meeting of Shareholders |
May 4, 2023 |
|
Bank of America Healthcare Conference |
May 9-11, 2023 |
|
Jefferies Healthcare Conference |
June 7-9, 2023 |
|
Goldman Sachs Global Healthcare Conference |
June 12-15, 2023 |
|
Citi European Healthcare Conference |
June 20-21, 2023 |
|
J.P. Morgan European Healthcare Conference |
June 22, 2023 |
|
Stifel European Healthcare Summit |
June 29-30, 2023 |
|
Half-Year 2023 Financial Results reporting* |
July 25, 2023 |
|
Citi BioPharma Conference |
September 6-7, 2023 |
|
Morgan Stanley Global Healthcare Conference |
September 11-14, 2023 |
|
Bank of America Global Healthcare Conference |
September 13-14, 2023 |
|
Baader Investment Conference |
September 18-22, 2023 |
|
9-month 2023 Financial Results reporting* |
October 24, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Financial information
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Corporate reports
The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.
Stock information
The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications